CDK9 and neoplasm: CDK9 inhibition using MC180295 reactivates epigenetically silenced genes in cancer by dephosphorylating the SWI/SNF protein BRG1, leading to the restoration of tumor suppressor gene expression, cell differentiation, and activation of endogenous retroviral genes.8